Filed by Social Capital Suvretta Holdings Corp. I
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Akili Interactive Labs, Inc.
Registration No.: 333-262706
Date: March 10, 2022
This filing relates to
the proposed merger of Akili Interactive Labs, Inc., a Delaware corporation (Target), with Karibu Merger Sub, Inc. (Merger Sub), a Delaware corporation and a wholly owned subsidiary of Social Capital Suvretta Holdings Corp.
I, a Cayman Islands exempted company limited by shares (SPAC), pursuant to the terms of that certain Agreement and Plan of Merger, dated as of January 26, 2022, by and among SPAC, Merger Sub and Target.
BOSTON(BUSINESS WIRE)Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive
treatments through game-changing technologies, today announced that co-founder and Chief Executive Officer, Eddie Martucci, will participate in a panel discussion at SXSW 2022, a conference that convenes a
global community of digital creatives with a shared pursuit of forward-thinking, cutting-edge ideas.
The session, Ushering in a New Class of
Disease-Modifying Digital Therapeutics, will be moderated by Georgia Mitsi, General Manager of Mental Health at Biogen. Joining Eddie Martucci as panelists are Brent Vaughan, Chief Executive Officer of Cognito Therapeutics and Nancy Isenberg,
Medical Director of the Center for Healthy Aging/Neurology at the Swedish Neuroscience Institute. Together, theyll discuss the science and engineering behind an emerging class of treatments that use novel neuro-physiology technologies to treat
therapeutic targets.
SXSW attendees can join the panel live at The Austin Marriott Downtown, Waterloo Ballroom 4, on Monday, March 14, at 2:30 p.m.
CT.
More information on the sessions and how to attend can be found at www.sxsw.com.
About Akili
Akili is pioneering the development of
cognitive treatments through game-changing technologies. Our approach of leveraging technologies designed to directly target the brain establishes a new category of medicine medicine that is validated through clinical trials like a drug or
medical device, but experienced like entertainment. Akilis platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain, informed by decades of research and validated through
rigorous clinical programs. Driven by Akilis belief that effective medicine can also be fun and engaging, Akilis products are delivered through captivating action video game experiences.